Clinical Trial Update: Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating early allogeneic hematopoietic cell transplantation for patients with relapsed or refractory high-grade myeloid neoplasms has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Blasts 10 Percent or More of Bone Marrow Nucleated Cells
• High Grade Malignant Neoplasm
• Myelodysplastic Syndrome
• Myelodysplastic Syndrome with Excess Blasts-2
• Myeloid Neoplasm
• Myelomonocytic Leukemia-2
• Previously Treated Myelodysplastic Syndrome

Snippet

Sponsor: University of Washington | Conditions: Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2 | Phase 2 | Status: COMPLETED | Results posted: 2021-03-22